Dialyse aktuell 2008; 12(1): 52-53
DOI: 10.1055/s-2008-1064893
Markt und Forschung

© Georg Thieme Verlag KG Stuttgart · New York

Selektive Vitamin-D-Rezeptor-Aktivierung - Schutz für Herz, Nieren und Gefäße

Further Information

Publication History

Publication Date:
11 March 2008 (online)

Also available at
 

Paricalcitol, ein Vitamin-D-Rezeptor-Aktivator (VDRA), der zur Therapie des sekundären Hyperparathyreoidismus (sHPT) bei Patienten mit chronischer Nierenerkrankung ("chronic kidney disease", CKD) zugelassen ist, senkt bei den Betroffenen nicht nur das pathologisch erhöhte Parathormon (PTH), sondern auch die Mortalität. Der selektive VDRA (sVDRA) Paricalcitol (Zemplar®) zeigt positive Effekte auf Herz, Gefäße und Nieren und kann so die Prognose von Dialysepatienten verbessern.

Literatur

  • 01 Agarwal R . Acharya M . Tian J . et al . Antiproteinuric effect of oral paricalcitol in chronic kidney disease.  Kidney Int. 2005;  68 2823-2828
    Search in Google Scholar
  • 02 Bodyak N . Ayus JC . Aichinger S . et al . Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals.  Proc Natl Acad Sci USA. 2007;  104 16810-16815
    Search in Google Scholar
  • 03 Brown AJ . Finch J . Slatopolsky E . et al . Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport.  J Lab Clin Med. 2002;  139 279-284
    Search in Google Scholar
  • 04 Cardús A . Panizo S . Parisi E . et al . Differential effects of vitamin D analogs on vascular calcification.  J Bone Miner Res. 2007;  22 860-866
    Search in Google Scholar
  • 05 Finch JL . Brown AJ . Slatopolsky E . et al . Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.  J Am Soc Nephrol. 1999;  10 980-985
    Search in Google Scholar
  • 06 Lee GH . Benner D . Regidor DL . Kalantar-Zadeh K . Impact of kidney bone disease and its management on survival of patients on dialysis.  J Ren Nutr. 2007;  17 (1) 38-44
    Search in Google Scholar
  • 07 Ma J . et al . J Am Soc Nephrol 2006; 15: 437A (SA-PO613). 
  • 08 Mizobuchi M . Finch JL . Martin DR . Slatopolsky E . Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.  Kidney Int. 2007;  72 (6) 709-715
    Search in Google Scholar
  • 09 Sprague SM . Llach F . Amdahl M . et al . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.  Kidney Int. 2003;  62 1483-1490
    Search in Google Scholar
  • 10 Teng M . Wolf M . Lowrie E . et al . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.  New Engl J Med. 2003;  349 446-456
    CrossrefSearch in Google Scholar
  • 11 Teng M . Wolf M . Ofsthun MN . et al . Activated injectable vitamin D and hemodialysis survival: a historical cohort study.  J Am Soc Nephrol. 2005;  16 1115-1125
    CrossrefSearch in Google Scholar
  • 12 Wu-Wong JR . Nakane M . Ma J . et al . Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.  Am J Physiol Renal Physiol. 2007;  293 F1592-F1604
    CrossrefSearch in Google Scholar
  • 13 Wu-Wong JR . Noonan W . Ma J . et al . Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.  J Pharmacol Exp Ther. 2006;  318 (1) 90-98
    CrossrefSearch in Google Scholar

01 Paricalcitol benefits in Renal disease Induced cardiac MOrbidity study

02 Effects of Paricalcitol capsules on Inflammation and Calcification regulation in CKD stage 5 patients

03 Selective VITamin D receptor activator [paricalcitol] for Albuminuria Lowering study